AC Immune (ACIU) Invested Capital (2016 - 2025)
AC Immune (ACIU) has disclosed Invested Capital for 9 consecutive years, with $151.2 million as the latest value for Q4 2024.
- On a quarterly basis, Invested Capital fell 24.19% to $151.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $151.2 million, a 24.19% decrease, with the full-year FY2024 number at $151.2 million, down 23.24% from a year prior.
- Invested Capital was $151.2 million for Q4 2024 at AC Immune, down from $199.4 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $275.1 million in Q4 2021 to a low of $151.2 million in Q4 2024.
- A 5-year average of $214.0 million and a median of $199.4 million in 2023 define the central range for Invested Capital.
- Peak YoY movement for Invested Capital: rose 7.66% in 2021, then plummeted 31.26% in 2022.
- AC Immune's Invested Capital stood at $255.5 million in 2020, then rose by 7.66% to $275.1 million in 2021, then tumbled by 31.26% to $189.1 million in 2022, then rose by 5.49% to $199.4 million in 2023, then decreased by 24.19% to $151.2 million in 2024.
- Per Business Quant, the three most recent readings for ACIU's Invested Capital are $151.2 million (Q4 2024), $199.4 million (Q4 2023), and $189.1 million (Q4 2022).